Maverix Biomics | GenomeWeb

Maverix Biomics

Maverix Biomics and Diagnomics have received CLIA validation for their pre-natal molecular diagnostic on a next-generation sequencing platform.

Researchers have sequenced and analyzed more than 50 feral and domestic cats in search of genetic variants involved in specific physical features and forms of disease. 

The BeHEARD competition will award more than $600,000 worth of technology products and services for rare disease research projects.

Under the terms of the agreement, the companies will combine software products and data to improve NGS analysis and interpretation

The Small Business Technology Transfer Award will fund research in collaboration with the University of Rochester to detect modifications in RNA transcripts.

Maverix Biomics has added analysis kits for analyzing variants in whole-genome, exome, and targeted resequencing data.

Maverix Biomics has added Jim Bristow to its scientific advisory board.

CollabRx has launched CancerRx, a new oncology application that runs on Apple's operating system. The app provides oncologists and pathologists with treatment options that are based on their patients' tumors and also offers a daily newsfeed from MedPage Today.

NEW YORK (GenomeWeb News) – Maverix Biomics said this week that it has extended an existing co-marketing agreement with Qiagen by integrating a second set of software products to support customers analyzing data from RNA-sequencing studies.

Increasing investments from venture capital firms in commercial bioinformatics indicates that the perceived value of the market is rising and suggests a level of optimism about the revenue potential of a segment of the life sciences space that historically hasn't been seen as par


In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.